Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$82,860.00+1.12%ETH$2,445.78+1.67%GOLD$4,136.50-0.15%OIL$98.26+0.45%
Smart Investors Daily
SID Premium
SL

NASDAQ · SLXN

Silexion Therapeutics Ltd.

Healthcare · Biotechnology

$0.15

Up+$0.00 (+0.52%)

Updated Oct 20, 2026, 11:29 PM

SID Score

2.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.69M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.14 – $5.45
Volume
5.11M
Avg. volume
205.66K

Price performance · SLXN

SLXN price history

1M range · 0 trading sessions · Daily adjusted prices

SLXN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SLXN news

The latest Smart Investors Daily articles mentioning SLXN.

Stock researchCompany · Overview

SLXN research

Overview

Company profile and research snapshot.

Company profile

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
SLXN recent ratings
DateFirmRatingTarget
Dec 15, 2025Litchfield HillsBuy—
Mar 20, 2025Maxim GroupBuy—
Nov 1, 2024Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer Integrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor stroma with subcutaneous dosing; first patient treated at Tel Aviv Sourasky Medical Center (Ichilov) Grand Cayman, Cayman Islands and Ramat Gan, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By